Company: SNY
Filing Date: 2025-07-17
Form Type: SC TO-T/A
Source: 0001193125-25-160176
Chunk: 1

Company: Sanofi
Filing Date: 2025-07-17
Form: SC TO-T/A
Chunk 1
---
. |

Check the following box if the filing is a final amendment reporting the results of the tender offer: ☐ If applicable, check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon:

| ☐ | Rule 13e-4(i) (Cross-Border Issuer Tender Offer) |

| ☐ | Rule 14d-1(d) (Cross-Border Third-Party Tender Offer) |

This Amendment No. 2 (this “”) amends and supplements the Tender Offer
Statement on Schedule TO filed by (i) Rothko Merger Sub, Inc., a Delaware corporation (“”) and an indirect wholly owned subsidiary of SANOFI, a French société anonyme (“”),
(ii) Parent, and (iii) Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent and direct parent of Purchaser (“”) on June 17, 2025 (together with any amendments or supplements thereto,
including this Amendment, the “”), relating to the offer by Purchaser to purchase all of the outstanding shares of common stock, par value, $0.001 per share (each a “” and collectively,
“”), of Blueprint Medicines Corporation., a Delaware corporation (the “”), for $129.00 per Share in cash, without interest (the “”) and subject to any withholding of
taxes required by applicable legal requirements, plus one (1) non-transferable contractual contingent value right (each, a “”) per Share, representing the right to receive
contingent payments of up to an aggregate amount of $6.00 per Share in cash, without interest, upon the achievement of one or both of the milestones on or prior to the expiration of the applicable milestone period set forth in the CVR Agreement (the
CVR, together with the Cash Offer Price, or any other amount paid pursuant to the Offer to the extent permitted under the Merger Agreement, the “”), on the terms and subject to the conditions set forth in the
Offer to Purchase, dated June 17, 2025 (together with any amendments or supplements thereto, the “”) and in the accompanying Letter of Transmittal, which are annexed to and filed with the Schedule TO as
Exhibits (a)(1)(A) and (a)(1)(B), respectively.

All information set forth in the Offer to Purchase, including Schedule I thereto, is incorporated by
reference herein in response to Items 1 through 9 and